Screener
Dianthus Therapeutics DNTH Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001690585-26-000022
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Stockholders’ equity: | ||
| Preferred stock; $0.001 par value per share; authorized shares – 10,000,000 at March 31, 2026 and December 31, 2025; issued and outstanding – none at March 31, 2026 and December 31, 2025 | — | — |
| Common stock; $0.001 par value per share; authorized shares – 150,000,000 at March 31, 2026 and December 31, 2025; issued and outstanding shares –54,582,749 and 43,223,090 at March 31, 2026 and December 31, 2025, respectively | 54 | 43 |
| Additional paid-in capital | 1,579,398 | 829,598 |
| Accumulated deficit | (377,563) | (336,729) |
| Accumulated other comprehensive (loss)/income | (575) | 489 |
| Total stockholders’ equity | 1,201,314 | 493,401 |
| Total liabilities and stockholders’ equity | $1,246,884 | $530,922 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dianthus Therapeutics's retained earnings?
- Dianthus Therapeutics (DNTH) reported retained earnings of -$377.56M in Q1 2026.
- How has Dianthus Therapeutics's retained earnings changed year-over-year?
- Dianthus Therapeutics's retained earnings decreased by 85.2% year-over-year, from -$203.9M to -$377.56M.
- What is the long-term trend for Dianthus Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), Dianthus Therapeutics's retained earnings has grown at a 5.8% compound annual growth rate (CAGR), from -$254.43M to -$336.73M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Dianthus Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude